Form 4: Bausch Health Grants RSUs to SVP, Controller & CAO

Bausch Health Companies Inc. awarded 45,868 restricted share units to Steven Hyosig Lee, SVP, Controller & CAO, as part of his compensation.

Summary

• Steven Hyosig Lee, SVP, Controller & CAO of Bausch Health Companies Inc. (BHC), was granted 45,868 common shares, no par value, in the form of Restricted Share Units (RSUs).
• The transaction occurred on February 25, 2026.
• These RSUs will vest one-third on each of the first three anniversaries following the grant date, contingent upon Mr. Lee's continued service.
• Vested RSUs are settled in common shares of Bausch Health Companies Inc.
• Following this transaction, Mr. Lee beneficially owns 73,239 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued alignment of executive interests with shareholder value through equity-based compensation, which is a healthy sign of corporate governance and incentive structure.

Positives

• The grant of Restricted Share Units (RSUs) to a key executive like the SVP, Controller & CAO, aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• RSU grants are a common and effective form of executive compensation, promoting a focus on sustained company growth and share value.

Future Outlook

The granted Restricted Share Units (RSUs) are scheduled to vest in three equal annual installments on the first, second, and third anniversaries of the grant date (February 25, 2026), subject to the reporting person's continued employment.

Industry Context

StockSavvy.ai notes that the award of Restricted Share Units (RSUs) to senior executives is a standard practice across various industries, particularly in the pharmaceutical and healthcare sectors, to attract, retain, and motivate key talent while aligning their incentives with long-term shareholder value creation. This type of compensation structure is widely accepted as a best practice in corporate governance.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) as a component of executive compensation is a common practice, comparable to compensation strategies observed at peer companies within the pharmaceutical and healthcare industries, such as Pfizer, Johnson & Johnson, and Merck.
• The vesting schedule of one-third annually over three years is a typical structure for RSU grants, designed to encourage long-term commitment and performance, consistent with global benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with shareholders, potentially leading to better long-term performance and increased share value.
• Employees: This type of compensation can serve as a positive signal regarding the company's commitment to retaining and incentivizing its leadership team.

Next Steps

• The Restricted Share Units (RSUs) will vest one-third on February 25, 2027, one-third on February 25, 2028, and the final one-third on February 25, 2029, assuming continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain information that would fundamentally alter the investment thesis for Bausch Health Companies Inc. While positive for management alignment, it is not a material event warranting a change in stock recommendation based solely on this filing.

Keywords

Bausch Health, BHC, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, Form 4